DOCSLIB.ORG

Annual Report and Accounts 2003/04

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report and Accounts 2003/04 Annual Report 2003/04 and Accounts Medical Research Council (MRC) Annual Report and Accounts 2003/04 Presented to Parliament by the Secretary of State, and by the Comptroller and Auditor General in pursuance of Schedule 1, Sections 2(2) and 3 (3) of the Science and Technology Act 1965. Sir Anthony Cleaver Chairman Professor Colin Blakemore Deputy Chairman and Chief Executive Ordered by the House of Commons to be printed on London: The Stationery Office 27 October 2004. Price: £17.85 HC 1123 The MRC The Medical Research Council (MRC) was originally set up in 1913 to administer public funds provided for medical research. It was incorporated under its present title by Royal Charter in 1920. A supplemental charter was granted in 1993 describing the MRC's new mission following the 1993 Government White Paper on Science and Technology. The MRC’s Royal Charter and Mission were amended in July 2003. The MRC receives an annual grant-in-aid from Parliament through the Office of Science and Technology (OST) and funds from other sources including government departments, international agencies, industry and medical research charities. The MRC Mission statement (in its shortened form) from July 2003 is to: • Encourage and support high-quality research with the aim of improving human health. • Produce skilled researchers, and to advance and disseminate knowledge and technology to improve the quality of life and economic competitiveness in the UK. • Promote dialogue with the public about medical research. MRC Council members 2003/04 Sir Anthony Cleaver Professor Ian MacLennan Chairman University of Birmingham Professor Colin Blakemore * Professor Alan North Deputy Chairman and Chief Executive University of Sheffield Dr David Armstrong ** Professor Sir John Pattison King’s College London Department of Health Dr E Mac Armstrong Professor Genevra Richardson Scottish Executive Health Department Queen Mary and Westfield College, University of London Sir William Castell Amersham plc Professor Nancy Rothwell University of Manchester Professor Kay Davies University of Oxford Professor John Savill University of Edinburgh Professor Dick Denton University of Bristol * New member appointed 1 October 2003 ** New member appointed 1 August 2003 Dr Peter Fellner Vernalis plc Outgoing membership: Mr Derek Flint Non-executive Director of Alliance & Leicester Professor Sir George Radda * Insurance plc Deputy Chairman and Chief Executive Dr Ruth Hall Professor Raymond Fitzpatrick ** The National Assembly for Wales University of Oxford Dr Chris Henshall * Appointment ended on 30 September 2003 Office of Science and Technology observer ** Appointment ended on 31 July 2003 Contents Foreword from the Chairman and the Chief Executive 2 Executive summary 4 Research 6 Scientific aims and objectives 6 Spending Review priorities 7 Major research developments and partnerships 8 Cross-cutting initiatives 14 International 15 Supporting research excellence 16 Publication output indicators 20 Investment in people 22 Human resources 22 Training 23 Technology transfer 26 MRC Technology 26 Technology transfer indicators 28 Communication 30 Operational 34 Good research practice and ethics 34 Effective business practice 36 Financial summary 42 Annual Accounts 2003/04 45 This report relates to the MRC’s activities from 1 April 2003 to 31 March 2004. A selection of outstanding achievements by MRC scientists during the year are highlighted in the MRC Annual Review 2003/04. Our website at www.mrc.ac.uk provides more detailed information about MRC activities and electronic versions of MRC publications. 1 Foreword Foreword from the Chairman and the Chief Executive Sir Anthony Cleaver Professor Colin Blakemore Chairman Deputy Chairman and Chief Executive With the arrival of a new Chief Executive, 2003/04 has been process, speed up grant processing, and ‘smooth’ our funding a year of transition, review and renewal. But it has also been from year to year. And to reflect the MRC’s strategic focus one of ongoing development, and when taking forward our on clinical research, the Physiological Medicine and Infections mission to improve human health we have been careful to Research Board has been reconfigured to create a Physiological build on the strengths that have made the MRC a world Systems and Clinical Sciences Board, and a separate board leader in medical research. This year brought further covering Infections and Immunity. We will now monitor the international recognition of the MRC’s track record. For new arrangements and continue to invite user feedback so example, the worldwide celebrations of the fiftieth anniversary that we can make any necessary refinements. of Watson and Crick’s elucidation of the structure of DNA, and Sir Peter Mansfield’s Nobel Prize for his pioneering work When drawing up the roadmap for our major infrastructure on magnetic resonance imaging. capital investments over the next 10-15 years, we set up a Task Force to draw up proposals for the MRC’s National Listening and responding to Government, the scientific Institute for Medical Research (NIMR). It comprised MRC community and the wider public was integral to our planning Council members, independent experts from the UK and in 2003/04. The public funds the MRC’s work, so its opinions abroad and senior NIMR scientists. Their interim report about medical research and health-related issues are very recommended that a renewed national institute, built around important to us. We are continually seeking ways to increase a core of current NIMR science, should be located in London. public involvement in our work, and our Consumer Liaison The MRC’s Council will consider the Task Force’s final Group has been renamed the Advisory Group on Public recommendations in July 2004. Other major investments Involvement to reflect this. In 2003/04 the MRC received a included the launch of a new £4m epidemiology initiative warm welcome at a series of roadshows hosted by universities centred on obesity, diabetes and osteoporosis research in active in medical research, at which we canvassed the scientific Cambridge, and the UK Stem Cell Bank that we set up in community’s views about MRC funding schemes. Their partnership with the Biotechnology and Biological Sciences valuable feedback influenced the major revision of our funding Research Council. schemes and procedures in February 2003. This year we took a fresh look at MRC’s support for clinical We have streamlined our grants system to create fewer, trials. We are actively seeking increased investment in clinical simpler, and more flexible schemes. They cater for researchers research, with a focus on translating basic research into at all stages of their careers, and will make it easier for us to benefits for patients. To do this we will need more researchers, fund research in partnership with other organisations. We increased funding for clinical research, and more effective have also introduced measures to simplify the peer-review ways to translate research findings into medical practice and 2 healthcare policy. These are the key components of our 2004 Spending Review bid. Our priorities were echoed in influential reports published this year by the Academy of Medical Sciences and the Biosciences Innovation and Growth Team. The Government’s Research for Patient Benefit Working Party recognised the MRC’s key role in clinical research, and we will be centrally involved in the UK Clinical Research Collaboration, which is bringing together clinicians, hospitals, industry and the voluntary sector to accelerate translational research and increase patient participation. Technology transfer is a crucial step in the journey from lab to clinic. Our dedicated technology transfer arm – MRC Technology (MRCT) – has made impressive progress in exploiting intellectual property arising from MRC-funded research. It has generated £60m in licensing income over the last four years, and a growing roster of MRC start-up companies that produce a steady stream of innovative healthcare products. In 2003 we launched a new Development Gap scheme to fund further research to develop MRC discoveries with commercial potential, and appointed an experienced biotechnology entrepreneur, Dr Roberto Solari, as MRCT Chief Executive in January. We are encouraged by Chancellor Gordon Brown’s budget announcement of a cash injection for medical research over the next four years, and will be working even more closely with the Government and the Health Departments to address national health priorities in the years ahead. As a new chapter in the MRC’s long history unfolds, we have much cause for optimism. We look forward to bringing you news of our progress in next year’s report. Chairman Deputy Chairman and Chief Executive 3 Executive summaryExecutive Executive summary Support for research • The MRC spent £235.6m (£209.1m resource and £26.5m capital) on its own research centres. • The MRC’s total spend on grants for research in universities and teaching hospitals was £180.2m, including training awards for post-graduate students and fellows. • The MRC launched six new grant schemes to replace the current twelve. The new schemes provide more flexibility for all applicants in terms of size and length of grants, and increased support for researchers at the beginning of their careers. Partnerships • The UK Stem Cell Bank (funded by the MRC and the Biotechnology and Biological Sciences Research Council) was officially opened. • The MRC has continued to work with the Wellcome Trust and the Department of Health to develop the
Load more

Recommended publications
  • ANNUAL REVIEW 1 October 2005–30 September
    WELLCOME TRUST ANNUAL REVIEW 1 October 2005–30 September 2006 ANNUAL REVIEW 2006 The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. It funds innovative biomedical research, in the UK and internationally, spending around £500 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing. www.wellcome.ac.uk THE WELLCOME TRUST The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. 123 CONTENTS BOARD OF GOVERNORS 2 Director’s statement William Castell 4 Advancing knowledge Chairman 16 Using knowledge Martin Bobrow Deputy Chairman 24 Engaging society Adrian Bird 30 Developing people Leszek Borysiewicz 36 Facilitating research Patricia Hodgson 40 Developing our organisation Richard Hynes 41 Wellcome Trust 2005/06 Ronald Plasterk 42 Financial summary 2005/06 Alastair Ross Goobey 44 Funding developments 2005/06 Peter Smith 46 Streams funding 2005/06 Jean Thomas 48 Technology Transfer Edward Walker-Arnott 49 Wellcome Trust Genome Campus As at January 2007 50 Public Engagement 51 Library and information resources 52 Advisory committees Images 1 Surface of the gut. 3 Zebrafish. 5 Cells in a developing This Annual Review covers the 2 Young children in 4 A scene from Y fruit fly. Wellcome Trust’s financial year, from Kenya. Touring’s Every Breath. 6 Data management at the Sanger Institute. 1 October 2005 to 30 September 2006. CONTENTS 1 45 6 EXECUTIVE BOARD MAKING A DIFFERENCE Developing people: To foster a Mark Walport The Wellcome Trust’s mission is research community and individual Director to foster and promote research with researchers who can contribute to the advancement and use of knowledge Ted Bianco the aim of improving human and Director of Technology Transfer animal health.
    [Show full text]
  • A DNA Database in the NHS: Your Freedom up for Sale?
    A DNA database in the NHS: Your freedom up for sale? May 2013 In April 2013, the Caldicott Committee, including Government Chief Scientist Sir Mark Walport, proposed new rules for data-sharing which would allow the Government to build a DNA database of the whole population of England in the NHS by stealth.1 The plan is to make NHS medical records and people’s genetic information available to commercial companies and to use public-private partnerships to build a system where all private information about every citizen is also accessible to the police, social workers, security services and Government. The Wellcome Trust, which was involved in the Human Genome Project and was led by Walport for ten years, has produced a plan which involves including a variant file, containing the whole genome of every person minus the reference genome, as an attachment to every medical record in the NHS in England.2 This data would be made available to ‘researchers’ (including commercial companies) for data-mining in the cloud and personalised risk assessments would be returned to individuals. The aim is to transform the NHS in line with proposals developed more than a decade ago by former GlaxoSmithKline Chairman Sir Richard Sykes. This is expected to massively expand the market for medicines, medical tests and other products, such as supplements and cholesterol-lowering margarines, by allowing products to be marketed to individuals based on personal risk assessments, created using statistical analysis of genetic data, medical records and other health information. The proposal to build a DNA database in the NHS was endorsed by the Human Genomics Strategy Group in 20123,4 and the Government (led by Prime Minister David Cameron) has quietly adopted this recommendation without telling members of the public.
    [Show full text]
  • Summarised Financial Statements 2012
    Summarised Financial Statements 2012 Contents Chairman’s Statement 02 02 Summary Trustee’s Report 04 04 Vision and Objects, Mission, Focus Areas 04 and Challenges Financial Review 06 Extracts from the Review of Investment Activities 08 Independent Auditors’ Report 10 10 Consolidated Statement of Financial Activities 11 Consolidated Balance Sheet 12 Consolidated Cash Flow Statement 13 Grants Awarded 14 Reference and Administrative Details 16 Chairman’s Statement Sustained investment in research can bring real benefits or Medicine which was shared by a dozens of genomes every day. Their former Governor of the Trust, work is driving the first wave of Professor Sir John Gurdon. His work stratified medicine, improving cancer showed that mature cells had the therapy for patients by examining the potential to be reprogrammed into genetics of individual tumours, and stem cells. Subsequent decades of revealing the genetic basis of the way investment in stem cell research have specific cancers respond to different brought us ever closer to realising the drugs. promise of stem cell therapies. At the same time, ever-improving We saw again this year how sustained technology is giving us an advantage investment in research can bring real against infectious diseases. A study benefits. Genetics has been one of the published this summer demonstrated Trust’s most focused areas of funding how modern genome sequencing Summary of Chairman’s since the mid-1990s. First, we sought could track methicillin-resistant Statement to decode the human genome; then Staphylococcus aureus (MRSA). we had to find ways to apply that Retrospective analysis of samples • We committed £701 million in grant knowledge.
    [Show full text]
  • Wellcome Trust Finance Plc (Incorporated in England and Wales Under the Companies Act 1985 with Registered Number 5857955) £275,000,000 4.75 Per Cent
    Wellcome Trust Finance plc (incorporated in England and Wales under the Companies Act 1985 with registered number 5857955) £275,000,000 4.75 per cent. Guaranteed Bonds due 2021 guaranteed (as described herein) by Wellcome Trust (a charity registered under the Charities Act 1993 with registered number 210183) Issue Price 98.902 per cent The £275,000,000 4.75 per cent. Guaranteed Bonds due 2021 (the “Bonds”) will be issued by Wellcome Trust Finance plc (the “Issuer”). The payment of all amounts due in respect of the Bonds will be unconditionally and irrevocably guaranteed pursuant to the terms of a guarantee (the “Guarantee”) given by The Wellcome Trust Limited (in its capacity as trustee of the Wellcome Trust). Interest on the Bonds is payable annually in arrear on 28 May in each year. Payments on the Bonds will be made without withholding or deduction for or on account of taxes of the United Kingdom to the extent described under “Terms and Conditions of the Bonds – Taxation”. The Bonds will mature on 28 May 2021 but may be redeemed before that date at the option of the Issuer in whole but not in part at any time at a redemption price which is equal to the higher of (i) their principal amount and (ii) a price calculated by reference to the yield on the relevant United Kingdom government stock, plus 0.10 per cent., in each case, together with accrued interest. See “Terms and Conditions of the Bonds – Redemption and Purchase”. The Bonds are also subject to redemption in whole but not in part, at their principal amount, together with accrued interest, at the option of the Issuer at any time in the event of certain changes affecting taxes of the United Kingdom.
    [Show full text]
  • IMPORTANT: You Must Read the Following Before Continuing. The
    IMPORTANT: You must read the following before continuing. The following applies to the Prospectus following this page, and you are therefore required to read this carefully before reading, accessing or making any other use of the Prospectus. In accessing the Prospectus, you agree to be bound by the following terms and conditions, including any modifications to them any time you receive any information from us as a result of such access. THE FOLLOWING PROSPECTUS MAY NOT BE FORWARDED OR DISTRIBUTED OTHER THAN AS PROVIDED BELOW AND MAY NOT BE REPRODUCED IN ANY MANNER WHATSOEVER. THIS PROSPECTUS MAY ONLY BE DISTRIBUTED OUTSIDE THE UNITED STATES TO PERSONS THAT ARE NOT U.S. PERSONS AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). ANY FORWARDING, DISTRIBUTION OR REPRODUCTION OF THIS DOCUMENT IN WHOLE OR IN PART IS UNAUTHORISED. FAILURE TO COMPLY WITH THIS DIRECTIVE MAY RESULT IN A VIOLATION OF THE SECURITIES ACT OR THE APPLICABLE LAWS OF OTHER JURISDICTIONS. NOTHING IN THIS ELECTRONIC TRANSMISSION CONSTITUTES AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITIES IN ANY JURISDICTION. THE SECURITIES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OR WITH ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS. Confirmation of your Representation: In order to be eligible to view this Prospectus or make an investment decision with respect to the securities, you must be a person other than a U.S.
    [Show full text]
  • Annual Report and Financial Statements
    Financial year 2014 Annual Report and Financial Statements Contents Chairman’s Statement 02 Trustee’s Report 04 Vision and objects, mission, focus areas and 04 challenges Financial Review 05 Review of Past and Future Activities 09 Review of Investment Activities 15 Structure and Governance 26 Remuneration Report 32 Social Responsibility 34 Independent Auditors 36 Audit Committee Report 37 Independent Auditors’ Report 39 Consolidated Statement of Financial Activities 45 Consolidated Balance Sheet 46 Statement of Financial Activities of the Trust 47 Balance Sheet of the Trust 48 Consolidated Cash Flow Statement 49 Notes to the Financial Statements 50 Reference and Administrative Details 90 Chairman’s Statement The best research for better health Creating cultures for research who we are and what we do, and has at the frontiers of medicine helped us achieve an ever more and health integrated approach within. This was a challenging first year for The built environment is a huge our Director, Dr Jeremy Farrar. As a influence on the way we work. The clinician and a researcher with Francis Crick Institute, a partnership expertise across global health and between the Trust, the Medical infectious diseases, his skills were in Research Council, Cancer Research high demand, particularly when it UK and several of London’s became clear that the Ebola virus universities, opens next year. It, too, outbreak in West Africa this year was has been designed to encourage an epidemic of unprecedented interdisciplinary working. As well as proportion. At the same time, Jeremy enhancing research partnerships, the was listening carefully to the views of Crick will bring biomedical research We have streamlined the his new colleagues at the Wellcome together with clinical skills and many framework for our funding Trust and of the research community other scientific disciplines.
    [Show full text]
  • Annual Review 2011
    Annual Review 2011 Highlights of the Wellcome Trust’s work in 2011, our 75th anniversary year, in which we redoubled our personal support for the brightest minds in research. Executive Board Wellcome Trust Mark Walport We are a global charitable foundation Director of the Wellcome Trust dedicated to achieving extraordinary Ted Bianco Director of Technology Transfer improvements in human and animal Simon Jeffreys health by supporting the brightest minds Chief Operating Officer in biomedical research and the medical David Lynn Head of Strategic Planning and Policy humanities. Clare Matterson Director of Medical Humanities Our ten-year Strategic Plan for 2010–20 and Engagement Kevin Moses provides the framework for how we intend Director of Science Funding to evolve our support to be even more John Stewart effective in achieving this aim. Head of Legal and Company Secretary Danny Truell Chief Investment Officer Our funding focuses on: As at December 2011 1. Supporting outstanding researchers 2. Accelerating the application of research 3. Exploring medicine in historical and Board of Governors cultural contexts. William Castell, Chairman Peter Rigby, Deputy Chairman Our five major challenges are: Kay Davies 1. Maximising the health benefits Peter Davies Christopher Fairburn of genetics and genomics Richard Hynes 2. Understanding the brain Anne Johnson 3. Combating infectious disease Roderick Kent Eliza Manningham-Buller 4. Investigating development, ageing Peter Smith and chronic disease As at December 2011 5. Connecting environment, nutrition
    [Show full text]
  • IMPORTANT: You Must Read the Following Before Continuing. The
    IMPORTANT: You must read the following before continuing. The following applies to the prospectus following this page (the “Prospectus”), and you are therefore required to read this carefully before reading, accessing or making any other use of the Prospectus. In accessing the Prospectus, you agree to be bound by the following terms and conditions, including any modifications to them any time you receive any information from us as a result of such access. THE FOLLOWING PROSPECTUS MAY NOT BE FORWARDED OR DISTRIBUTED OTHER THAN AS PROVIDED BELOW AND MAY NOT BE REPRODUCED IN ANY MANNER WHATSOEVER. THIS PROSPECTUS MAY ONLY BE DISTRIBUTED OUTSIDE THE UNITED STATES TO PERSONS THAT ARE NOT U.S. PERSONS AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). ANY FORWARDING, ANY OTHER DISTRIBUTION OR ANY REPRODUCTION OF THIS PROSPECTUS IN WHOLE OR IN PART IS UNAUTHORISED. FAILURE TO COMPLY WITH THIS DIRECTIVE MAY RESULT IN A VIOLATION OF THE SECURITIES ACT OR THE APPLICABLE LAWS OF OTHER JURISDICTIONS. NOTHING IN THIS ELECTRONIC TRANSMISSION CONSTITUTES AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITIES IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO DO SO. THE SECURITIES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OR WITH ANY SECURITIES REGULATORY AUTHORITY OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS. Confirmation of your Representation: In order to be eligible to view this Prospectus or make an investment decision with respect to the securities, you must be a person other than a U.S.
    [Show full text]
  • Wellcome Trust Annual Review 2008
    WELLCOME TRUST ANNUAL REVIEW 1 October 2007–30 September 2008 September 2007–30 October 1 REVIEW ANNUAL TRUST WELLCOME ANNUAL REVIEW 2008 The Wellcome Trust is the largest charity in the UK. It funds innovative biomedical research, in the UK and internationally, spending over £600 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing. www.wellcome.ac.uk www.wellcome.ac.uk THE wellcome trust The Wellcome Trust is the largest charity in the UK. It funds innovative biomedical research, in the UK and internationally, and supports public debate about biomedical research and its impact on health and wellbeing. 1 2 3 4 CONTENTS BOARD OF GOVERNORS 2 Director’s statement William Castell This Annual Review covers the Chairman Wellcome Trust’s financial year, from Achieving our objectives 1 October 2007 to 30 September 2008. Adrian Bird 4 Advancing knowledge Deputy Chairman 16 Using knowledge Kay Davies 24 Engaging society Christopher Fairburn 30 Developing people Richard Hynes 36 Facilitating research Roderick Kent 40 Developing our organisation Eliza Manningham-Buller Peter Rigby The year in review Peter Smith 41 Corporate activities Edward Walker-Arnott 42 Financial summary 2007/08 As at January 2009 44 Funding developments 2007/08 46 Streams funding 2007/08 48 Technology Transfer 49 Wellcome Trust Genome Campus 50 Public Engagement 51 Wellcome Collection 52 Advisory committees Cover image Salbutamol crystals. Images 1 Practical science at the launch of Project Enthuse. 4 Equipment from the lab of Dr Thomas Down.
    [Show full text]
  • Wellcome Trust Annual Report and Financial Statements 2015 Is © the Wellcome Trust and Is Licensed Under Creative Commons Attribution 2.0 UK
    Financial year 2015 Annual Report and Financial Statements Contents Chair’s Statement 02 Vision and objects, mission, focus areas and 04 challenges Trustee’s Report Strategic Report 05 Financial Review 06 Review of Past and Future Activities 08 Review of Investment Activities 12 Risk Management 24 Structure and Governance 26 Remuneration Report 29 Social Responsibility 31 Independent Auditors 32 Audit Committee Report 33 Independent Auditors’ Report 35 Consolidated Statement of Financial Activities 42 Consolidated Balance Sheet 43 Statement of Financial Activities of the Trust 44 Balance Sheet of the Trust 45 Consolidated Cash Flow Statement 46 Notes to the Financial Statements 47 Reference and Administrative Details 88 Chair’s Statement I am delighted to introduce this priority areas. This extra focus Annual Report for the first time as becomes possible because of the Chair of the Wellcome Trust. I was a continued success of our investments. Governor for seven years before becoming Chair on 1 October 2015. It is a great privilege not only to lead Investments this extraordinary charity but also to be able to build on the achievements The investment portfolio added a of my predecessor, Sir William pleasing £1.1 billion (return of 6.1%) Castell, who was Chair for a decade. in the year to September 2015, despite Always a strong advocate of a difficult market backdrop. Building bioscience and its ability to transform on six prior years of positive human health, during his tenure he performance for the portfolio, this also pushed medical innovation, brings the cumulative return since the science education, public engagement onset of the financial crisis in with science and greater involvement September 2008 to 92%, equating to with industry.
    [Show full text]
  • Wellcome Trust Annual Review 2007
    WELLCOME TRUST ANNUAL REVIEW 1 October 2006–30 September 2007 ANNUAL REVIEW 2007 The Wellcome Trust is the largest charity in the UK. It funds innovative biomedical research, in the UK and internationally, spending over £500 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing. www.wellcome.ac.uk THE WELLCOME TRUST The Wellcome Trust is the largest charity in the UK. It funds innovative biomedical research, in the UK and internationally, and supports public debate about biomedical research and its impact on health and wellbeing. 123 CONTENTS BOARD OF GOVERNORS 2 Director’s statement William Castell Chairman Achieving our objectives Adrian Bird 4 Advancing knowledge Deputy Chairman 16 Using knowledge Kay Davies 24 Engaging society Christopher Fairburn 30 Developing people Patricia Hodgson 36 Facilitating research Richard Hynes 40 Developing our organisation Peter Rigby The year in review Alastair Ross Goobey* 41 Corporate activities Peter Smith 42 Financial summary 2006/07 Edward Walker-Arnott 44 Funding developments 2006/07 As at January 2008 46 Streams funding 2006/07 *While finalising this publication, we were saddened to learn that Alastair Ross Goobey had died, following a 48 Technology Transfer long illness. Alastair was an outstanding Governor and extraordinary friend of the Wellcome Trust. A Governor 49 Wellcome Trust Genome Campus since 2002, his advice was instrumental in helping to develop the investments of the Trust. He took a 50 Public Engagement great interest in all aspects of our activities and will be 51 Wellcome Collection sadly missed by those who worked with him.
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (Rule 14c-101) INFORMATION REQUIRED IN INFORMATION STATEMENT SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: x Preliminary Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) o Definitive Information Statement RADIUS HEALTH, INC. (Name of Registrant As Specified In Its Charter) Payment of Filing Fee (Check the appropriate box): x No fee required. o Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11. (1) Title of each class of securities to which transaction applies: N/A. (2) Aggregate number of securities to which transaction applies: N/A. (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): N/A. (4) Proposed maximum aggregate value of transaction: N/A. (5) Total fee paid: N/A. o Fee paid previously with preliminary materials. o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: N/A. (2) Form, Schedule or Registration Statement No.: N/A. (3) Filing Party: N/A.
    [Show full text]